Loading...
ACS Chemical Neuroscience Molecule Spotlight on Suvorexant
[Image: see text] Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Chemical
Society
2012
|
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3447389/ https://ncbi.nlm.nih.gov/pubmed/23024835 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cn300086a |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|